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SCIENTIFIC OPINION 
Scientific Opinion on the modification of the authorisation of a health claim 
related to cocoa flavanols and maintenance of normal endothelium-
dependent vasodilation pursuant to Article 13(5) of Regulation (EC) 
No 1924/20061 following a request in accordance with Article 19 of 
Regulation (EC) No 1924/2006 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)2,3 
European Food Safety Authority (EFSA), Parma, Italy 
This scientific output, published on 22 July 2014, replaces the earlier version published on 05 May 
 2014* 
ABSTRACT 
Following an application from Barry Callebaut Belgium NV, submitted pursuant to Article 19 of Regulation (EC) 
No 1924/2006 via the Competent Authority of Belgium, the EFSA Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver an opinion on the modification of the authorisation of a health claim 
related to “cocoa flavanols help maintain the elasticity of blood vessels, which contributes to normal blood flow”, 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006. The modification concerns an extension of the 
authorised conditions of use of the claim to a high-flavanols (HF) cocoa extract to be consumed in capsules, 
tablets or added to “other foods, including beverages”. Cocoa flavanols, which are the subject of the health claim, 
have been sufficiently characterised. Maintenance of normal endothelium-dependent vasodilation is a beneficial 
physiological effect.  The Panel concludes that a cause and effect relationship has been established between the 
consumption of cocoa flavanols in the HF cocoa extract (i.e. in capsules or tablets) and maintenance of normal 
endothelium-dependent vasodilation. In order to obtain the claimed effect, 200 mg of cocoa flavanols should be 
consumed daily. This amount could be provided by less than one gram of HF cocoa extract in capsules or tablets, 
and can be consumed in the context of a balanced diet. The target population is the general population. 
© European Food Safety Authority, 2014 
                                                     
1 On request from the Competent Authority of Belgium following an application by Barry Callebaut Belgium NV, Question 
No EFSA-Q-2013-00832, adopted on 10 April 2014. 
2 Panel members: Carlo Agostoni, Roberto Berni Canani, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, 
Sébastien La Vieille, Rosangela Marchelli, Ambroise Martin, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna 
Nowicka, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, 
Dominique Turck and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3 Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis 
Bresson, Susan Fairweather-Tait, Marina Heinonen, Ambroise Martin, Hildegard Przyrembel, Yolanda Sanz, Alfonso 
Siani, Anders Sjödin, Sean (J.J.) Strain, Inge Tetens, Hendrik Van Loveren, Hans Verhagen and Peter Willatts for the 
preparatory work on this scientific opinion. 
* An editorial amendment was carried out that does not materially affect the contents or outcome of this Scientific Opinion 
To avoid confusion, the original version has been removed from the EFSA Journal, but is available on request, as is a 
version showing all the changes made. 
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SUMMARY 
Following an application from Barry Callebaut Belgium NV, submitted pursuant to Article 19 of 
Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the EFSA Panel on Dietetic 
Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the modification of the 
authorisation of a health claim related to “cocoa flavanols help maintain the elasticity of blood 
vessels, which contributes to normal blood flow”, pursuant to Article 13(5) of Regulation (EC) 
No 1924/2006, which was authorised by Commission Regulation No 851/2013. The authorised 
conditions of use of the claim are: “Information shall be given to the consumer that the beneficial 
effect is obtained with a daily intake of 200 mg of cocoa flavanols. The claim can be used only for 
cocoa beverages (with cocoa powder) or for dark chocolate which provide at least a daily intake of 
200 mg of cocoa flavanols with a degree of polymerisation 1-10”. 
The modification concerns an extension of the authorised conditions of use of the claim to a high-
flavanol (HF) cocoa extract to be consumed in capsules, tablets or added to “other foods, including 
beverages”. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence and including a request for the protection of proprietary data. 
The Panel notes that cocoa flavanols, which are the subject of the health claim, have been sufficiently 
characterised.  
The Panel considers that maintenance of normal endothelium-dependent vasodilation is a beneficial 
physiological effect. The target population is the general healthy adult population. 
In the partially-blinded, controlled, cross-over study, which was provided by the applicant as being 
pertinent to the health claim, six healthy subjects were randomised to consume cocoa flavanols from 
different formulations: cocoa extract in capsules, cocoa powder and dark chocolate bars. Plasma 
concentrations of epicatechins, which are likely to be responsible for the acute effect of cocoa 
flavanols on endothelium-dependent flow-mediated vasodilation, were measured at different time 
points after the consumption of the different formulations. The absorption of epicatechins from the 
HF cocoa extract in capsules when consumed with water was not lower than that observed for 
epicatechins in HF cocoa powder or HF dark chocolate, the food matrices for which the health claim 
has been authorised.    
Two studies were provided by the applicant as supportive of the health claim. The Panel considers 
that, in the absence of a direct comparison between the food matrices investigated in these studies 
(milk chocolate drink and nut cream) and cocoa powder or dark chocolate, no conclusions can be 
drawn from these studies for the extension of the conditions of use to the food matrices investigated in 
the studies.  
In weighing the evidence, the Panel took into account that the absorption of epicatechins from HF 
cocoa extract in capsules when consumed with water was not lower than that observed for 
epicatechins in HF cocoa powder or HF dark chocolate in a human intervention study. The Panel also 
took into account that, even if epicatechins are likely to be responsible for the acute effect of cocoa 
flavanols on endothelium-mediated vasodilation rather than for the long-term effect, it is unlikely that 
daily consumption of cocoa flavanols in the HF cocoa extract would have different long-term effects 
on endothelium-mediated vasodilation than cocoa flavanols in cocoa powder or dark chocolate. The 
Panel considers that the bioavailability of cocoa flavanols from HF cocoa extract in capsules and in 
tablets is not different from HF cocoa powder or dark chocolate.  
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The Panel concludes that a cause and effect relationship has been established between the 
consumption of cocoa flavanols in the HF cocoa extract (i.e. in capsules or tablets) and maintenance 
of normal endothelium-dependent vasodilation. 
In order to obtain the claimed effect, 200 mg of cocoa flavanols should be consumed daily. This 
amount could be provided by less than one gram (0.25-0.67 g) of HF cocoa extract in capsules or 
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BACKGROUND 
Regulation (EC) No 1924/20064 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
The same Regulation, as referred to in Article 19, also lays down provisions for modification, 
suspension and revocation of authorisations. The procedures laid down in Article 15 and 18 shall 
apply mutatis mutandis. 
According to Article 18 of that Regulation, an application for the modification, suspension or 
revocation of authorisations of health claims included in the Community list of permitted claims 
referred to in Art 13(3) shall be submitted by the applicant to the national competent authority of a 
Member State, who will make the application and any supplementary information supplied by the 
applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
• The application was received on 17/10/2013. 
• The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. The application included a request for the protection of 
proprietary data. 
• The scientific evaluation procedure started on 06/11/2013. 
• On 22/01/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application and the clock 
was stopped on 03/02/2014 in compliance with Article 18(3) of Regulation (EC) No 
1924/2006. 
• On 14/02/2014, EFSA received the requested information and the clock was restarted. 
• During its meeting on 10/04/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to cocoa flavanols 
and maintenance of normal endothelium-dependent vasodilation.  
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 19 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: cocoa flavanols and maintenance 
of normal endothelium-dependent vasodilation.  
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of cocoa flavanols, a positive assessment of its safety, nor a decision on whether cocoa 
flavanols is, or is not, classified as a foodstuff. It should be noted that such an assessment is not 
foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Barry Callebaut Belgium NV, Aalstersestraat 122, B-9280 Lebbeke-
Wieze, Belgium. 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006 for one unpublished study report (ProDigest, 2012). The applicant 
also claimed confidentiality rights for information pertaining to the composition and the 
manufacturing process of the cocoa extract.  
Food/constituent as stated by the applicant 
According to the applicant, the food constituent that is the subject of the health claim is cocoa 
flavanols. 
Health relationship as claimed by the applicant 
The applicant indicated that a cause and effect relationship between the consumption of cocoa 
flavanols and endothelium-dependent vasodilation has already been established (EFSA NDA Panel, 
2012; Regulation (EC) No 851/2013). 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Cocoa flavanols help 
maintain the elasticity of blood vessels, which contributes to normal blood flow”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is the general healthy adult population. 
In order to obtain the claimed effect, 200 mg cocoa flavanols should be consumed daily. As an 
alternative to 2.5 g of high-flavanol (HF) cocoa powder or 10 g of HF dark chocolate (EFSA NDA 
Panel, 2012), this amount could also be provided by 0.25-0.67 g of HF cocoa extract in the form of 
capsules, tablets or added to food applications as such. The flavanols’ content in the HF cocoa extract 
varies between 80% and 30% flavanols (DP1-10). The HF cocoa extract is easily dissolvable in water, 
and can be consumed in the context of a balanced diet. The amount of HF cocoa extracts added to 
food applications, including beverages, should accommodate the highest possible losses due to 
treatment of the food. 
ASSESSMENT 
The Panel has already adopted an opinion on the scientific substantiation of a health claim related to 
cocoa flavanols and maintenance of normal endothelium-dependent vasodilation with a favourable 
outcome pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (EFSA NDA Panel, 2012). On 
3 September 2013, the European Commission adopted Regulation No 851/20135, which authorised a 
health claim related to “cocoa flavanols help maintain the elasticity of blood vessels, which 
contributes to normal blood flow”. The authorised conditions of use of the claim are: “Information 
shall be given to the consumer that the beneficial effect is obtained with a daily intake of 200 mg of 
                                                     
5 Commission Regulation (EU) No 851/2013 of 3 September 2013 authorising certain health claims made on foods, other 
than those referring to the reduction of disease risk and to children’s development and health and amending Regulation 
(EU) No 432/2012. OJ L 235, 4.9.2013, p. 3–7. 
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cocoa flavanols. The claim can be used only for cocoa beverages (with cocoa powder) or for dark 
chocolate which provide at least a daily intake of 200 mg of cocoa flavanols with a degree of 
polymerisation 1-10”. 
With the present application, the applicant has requested an extension of the conditions of use to a HF 
cocoa extract. The amount of 200 mg of cocoa flavanols can be provided by 0.25-0.67 g of HF cocoa 
extract in capsules or tablets. In the HF cocoa extract, monomeric flavanols (epicatechin and catechin) 
account for about 23 % of total flavanols (ProDigest, 2012). Information pertaining to the 
manufacturing process and the nutritional composition of the HF cocoa extract has been provided. 
Thirty-nine months stability data of the HF cocoa extracts with different flavanols content and two 
months stability data of the HF cocoa extract in water-based beverages have been provided. 
The applicant proposes that the HF cocoa extract providing 200 mg of cocoa flavanols could be 
consumed in capsules or tablets or added to “other foods, including beverages”, in order to obtain the 
claimed effect.  
Thus, the present opinion will address whether the conditions of use for this claim could be extended 
to the HF cocoa extract under the proposed uses (consumed in capsules, tablets or “other foods, 
including beverages”). 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is cocoa flavanols.  
The Panel notes that cocoa flavanols, which are the subject of the health claim, have been sufficiently 
characterised (EFSA NDA Panel, 2012).  
2. Relevance of the claimed effect to human health 
The Panel considers that maintenance of normal endothelium-dependent vasodilation is a beneficial 
physiological effect (EFSA NDA Panel, 2012). The target population proposed by the applicant is the 
general healthy adult population. 
3. Scientific substantiation of the claimed effect 
In order to apply for this extension of the conditions of use, the applicant performed a literature search 
in PubMed to retrieve comparative studies on the bioavailability of epicatechins, which are 
considered by the applicant to be responsible for the claimed effect, from different cocoa 
formulations. Various combinations of the following terms were used in the literature search, which 
was limited to “humans” and “clinical trial”: “cocoa”, “capsule”, “tablet”, “extract”, “epicatechin”, 
“flavanols”, “flavan-3-ols” and “pharmacokinetics”. No pertinent studies were identified by the 
applicant through this literature search.  
The Panel noted that cocoa flavanols (mostly epicatechins) may exert an acute effect on endothelium-
dependent flow-mediated dilation (ED-FMD) by enhancing nitric oxide production in the endothelium 
each time they are consumed. The Panel also noted that the evidence provided in support of 
mechanisms by which repeated consumption of cocoa flavanols may induce longer-term effects on 
fasting ED-FMD was weak and may have been related more to the gut metabolism of procyanidins 
and the fraction of epicatechin which is not absorbed in the small intestine, than to the fraction of 
epicatechin which is absorbed up to four to six hours after consumption (EFSA NDA Panel, 2012). 
The applicant provided the unpublished study report by ProDigest (2012) as being pertinent to the 
health claim. This is a randomised, partially-blinded, controlled, cross-over study which compared 
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plasma concentrations of epicatechins at different time points after consumption of cocoa flavanols 
from different formulations (i.e. cocoa extract in capsules vs. cocoa powder vs. dark chocolate in 
bars).  
Six healthy subjects (three men, mean age 26.7±10.3 years) were randomised to consume a 
pre-established sequence of five cocoa formulations in a single dose with a wash-out period in 
between of at least five days: HF cocoa extract in capsules (449 mg of flavanols per portion), 
low-flavanol (LF) and HF cocoa powder (27 mg and 459 mg of flavanols per portion, respectively), 
and LF and HF dark chocolate (60 mg and 460 mg of flavanols per portion, respectively). For the 
different cocoa formulations the epicatechin and catechin content per portion was provided: 96 mg 
and 7 mg in the HF cocoa extract in capsules, 2 mg and 4 mg in the LF cocoa powder, 95 mg and 29 
mg in the HF cocoa powder, 14 mg and 6 mg in the LF dark chocolate, and 86 mg and 11 mg in the 
HF dark chocolate. The Panel notes that the monomeric flavanol/total flavanol ratio in the three HF 
formulations (cocoa powder, dark chocolate and cocoa extract) was comparable (22-27%). Although 
it was possible to identify the different type of cocoa formulations given to participants (i.e. capsules, 
powder sachet and chocolate bars), neither investigators nor participants were able to distinguish the 
HF and LF study products. Upon a request by EFSA for clarification on the selection of the sample 
size, the applicant indicated that the sample size was based on a previous study with a similar design 
which had investigated the rate and extent of absorption of epicatechins from five different chocolate 
matrices, and in which six individuals were sufficient to detect relevant differences between the 
interventions (Neilson et al., 2009). 
After an overnight fast (except for the consumption of water which was allowed), subjects consumed 
the study products with 200 mL of water at the clinical facility and after two hours they consumed a 
standardised meal under the researchers’ supervision. Subjects were requested to refrain from 
consuming HF-containing products for two days prior to each study day. Blood samples for the 
detection of plasma epicatechins were taken at baseline (t = 0) and then at 0.5, 1, 2, 4, and 6 hours 
after consumption of the study products. Maximum plasma concentrations achieved (Cmax), time to 
maximum concentrations observed (Tmax) and area under the curve (AUC) for plasma epicatechins 
were analysed using a General Linear Model. Differences between periods were determined based on 
the Least Significant Difference test. Cmax and AUC values were significantly higher for HF dark 
chocolate and HF cocoa powder compared with their LF controls. Cmax, Tmax and AUC did not differ 
significantly between HF cocoa extract in capsules and HF cocoa powder. However, the AUC for HF 
cocoa extract in capsules was significantly higher than the AUC for HF dark chocolate (p = 0.03) and 
not significantly different from the AUC for HF cocoa powder. Cmax for HF cocoa extract in capsules 
was not significantly different from Cmax for HF dark chocolate and Cmax for HF cocoa powder. The 
Panel notes that the amount of flavanols per portion used in this study was more than double the 
amount required to achieve the claimed effect, as well as the amount of epicatechins generally 
contained in 200 mg of cocoa flavanols. However, the Panel considers that the absorption of 
epicatechins from 200 mg of flavanols in the HF cocoa extract in capsules, when consumed with 
water, would not be lower than that observed for epicatechins from the same amount of flavanols in 
cocoa powder or dark chocolate, the food matrices for which the health claim has been authorised.    
Through the literature search, the applicant identified two studies as supportive of the health claim. 
The studies investigated plasma concentrations of epicatechins or epicatechins plus catechins after 
consumption of a milk-containing or a milk-free chocolate drink (Keogh et al., 2007) or a nut cream 
(Vitaglione et al., 2013) containing HF cocoa extracts. Considering that the availability of cocoa 
flavanols in either cocoa powder or dark chocolate has not been investigated in these studies, the 
applicant was requested to provide a rationale on how these studies could provide evidence for an 
extension of the conditions of use of cocoa flavanols consumed as cocoa extract. The applicant 
acknowledged that neither study directly compared the availability of epicatechins from the tested 
food matrices (i.e. chocolate drinks and nut cream) against the authorised food matrices (i.e. cocoa 
powder and dark chocolate), and therefore did not consider that these studies were directly pertinent 
to the health claim but rather were only supportive. The Panel considers that, in the absence of a 
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direct comparison between the food matrices investigated and the authorised food matrices, no 
conclusions can be drawn from these two studies for the extension of the conditions of use to the food 
matrices investigated in the studies. 
In weighing the evidence, the Panel took into account that the absorption of epicatechins from HF 
cocoa extract in capsules when consumed with water was not lower than that observed for 
epicatechins in HF cocoa powder or HF dark chocolate in a human intervention study. The Panel also 
took into account that, even if epicatechins are likely to be responsible for the acute effect of cocoa 
flavanols on endothelium-mediated vasodilation rather than for the long-term effect, it is unlikely that 
daily consumption of cocoa flavanols in the HF cocoa extract would have different long-term effects 
on endothelium-mediated vasodilation than cocoa flavanols in cocoa powder or dark chocolate. The 
Panel considers that the bioavailability of cocoa flavanols from HF cocoa extract in capsules and in 
tablets is not different from HF cocoa powder or dark chocolate.  
The Panel concludes that a cause and effect relationship has been established between the 
consumption of cocoa flavanols in the HF cocoa extract (i.e. in capsules or tablets) and maintenance 
of normal endothelium-dependent vasodilation. 
The Panel could not have reached its conclusions without the human intervention study claimed as 
proprietary by the applicant (ProDigest, 2012, unpublished). 
4. Panel’s comments on the proposed wording 
See previous assessment of the EFSA NDA Panel (2012) and Commission Regulation6 dated 
3 September 2013.  
5. Conditions and restrictions of use  
In order to obtain the claimed effect, 200 mg of cocoa flavanols should be consumed daily. This 
amount could be provided by less than one gram (0.25-0.67 g) of HF cocoa extract in capsules or 
tablets. This amount of HF cocoa extract can be consumed in the context of a balanced diet. The 
target population is the general population. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
• The food constituent, cocoa flavanols, which is the subject of the claim, is sufficiently 
characterised.  
• Maintenance of normal endothelium-dependent vasodilation is a beneficial physiological 
effect.  
• A cause and effect relationship has been established between the consumption of cocoa 
flavanols in the HF cocoa extract (i.e. in capsules or tablets) and maintenance of normal 
endothelium-dependent vasodilation. 
• In order to obtain the claimed effect, 200 mg of cocoa flavanols should be consumed daily. 
This amount could be provided by less than one gram (0.25-0.67 g) of HF cocoa extract in 
                                                     
6 Commission Regulation (EU) No 851/2013 of 3 September 2013 authorising certain health claims made on foods, other 
than those referring to the reduction of disease risk and to children’s development and health and amending Regulation 
(EU) No 432/2012. OJ L 235, 4.9.2013, p. 3–7. 
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capsules or tablets. This amount of HF cocoa extract can be consumed in the context of a 
balanced diet. The target population is the general population. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on cocoa flavanols and maintenance of normal endothelium-dependent 
vasodilation pursuant to Article 13(5) of Regulation (EC) No 1924/2006 following a request in 
accordance with Article 19 of the afore-mentioned Regulation (Claim serial No: 00398_BE). October 
2013. Submitted by Barry Callebaut Belgium NV. 
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ABBREVIATIONS 
AUC  area under the curve 
Cmax  maximum plasma concentration 
ED-FMD endothelium-dependent flow-mediated dilation 
HF  high-flavanol 
LF  low-flavanol 
Tmax  time to maximum concentrations observed 
